Intravenous iron therapy for heart failure and iron deficiency: An updated meta‐analysis of randomized clinical trials
<p dir="ltr">Heart failure (HF) patients frequently exhibit iron deficiency, which is associated with a poor prognosis. Although various trials have been conducted, it is uncertain if intravenous (IV) iron replenishment improves clinical outcomes in HF patients with iron deficiency....
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513541637144576 |
|---|---|
| author | Mushood Ahmed (19231379) |
| author2 | Aimen Shafiq (21767660) Hira Javaid (16729233) Priyansha Singh (8265666) Haania Shahbaz (22045970) Muhammad Talha Maniya (22045973) Hritvik Jain (19757091) Najwa Shakir (22045976) Huzaifa Ahmad Cheema (13129113) Adeel Ahmad (3953720) Wajeeh Ur Rehman (18702910) Gabriel Yeap (22045979) Abdulqadir J. Nashwan (11659453) Abdul Mannan Khan Minhas (11640598) Raheel Ahmed (450330) Marat Fudim (12051803) Gregg C. Fonarow (8135523) |
| author2_role | author author author author author author author author author author author author author author author author |
| author_facet | Mushood Ahmed (19231379) Aimen Shafiq (21767660) Hira Javaid (16729233) Priyansha Singh (8265666) Haania Shahbaz (22045970) Muhammad Talha Maniya (22045973) Hritvik Jain (19757091) Najwa Shakir (22045976) Huzaifa Ahmad Cheema (13129113) Adeel Ahmad (3953720) Wajeeh Ur Rehman (18702910) Gabriel Yeap (22045979) Abdulqadir J. Nashwan (11659453) Abdul Mannan Khan Minhas (11640598) Raheel Ahmed (450330) Marat Fudim (12051803) Gregg C. Fonarow (8135523) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mushood Ahmed (19231379) Aimen Shafiq (21767660) Hira Javaid (16729233) Priyansha Singh (8265666) Haania Shahbaz (22045970) Muhammad Talha Maniya (22045973) Hritvik Jain (19757091) Najwa Shakir (22045976) Huzaifa Ahmad Cheema (13129113) Adeel Ahmad (3953720) Wajeeh Ur Rehman (18702910) Gabriel Yeap (22045979) Abdulqadir J. Nashwan (11659453) Abdul Mannan Khan Minhas (11640598) Raheel Ahmed (450330) Marat Fudim (12051803) Gregg C. Fonarow (8135523) |
| dc.date.none.fl_str_mv | 2024-07-04T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1002/ehf2.14905 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Intravenous_iron_therapy_for_heart_failure_and_iron_deficiency_An_updated_meta_analysis_of_randomized_clinical_trials/29899172 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Ferric carboxymaltose Heart failure Iron deficiency Intravenous iron |
| dc.title.none.fl_str_mv | Intravenous iron therapy for heart failure and iron deficiency: An updated meta‐analysis of randomized clinical trials |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Heart failure (HF) patients frequently exhibit iron deficiency, which is associated with a poor prognosis. Although various trials have been conducted, it is uncertain if intravenous (IV) iron replenishment improves clinical outcomes in HF patients with iron deficiency. A comprehensive literature search was conducted using PubMed/MEDLINE, Embase, and the Cochrane Library from inception till 15 September 2023 to retrieve randomized controlled trials (RCTs) that compared IV iron therapy with placebo or standard of care in patients with HF and iron deficiency. Clinical outcomes were assessed by generating forest plots using the random‐effects model and pooling odds ratios (ORs) or weighted mean differences (WMDs). Fourteen RCTs with 6651 patients were included. IV iron therapy showed a significantly reduced incidence of the composite of first heart failure hospitalization (HHF) or cardiovascular (CV) mortality as compared with the control group (OR = 0.73, 95% CI: 0.58 to 0.92). The IV iron therapy resulted in a trend towards lower CV mortality (OR = 0.88, 95% CI: 0.76 to 1.01), 1‐year all‐cause mortality (OR = 0.85, 95% CI: 0.71 to 1.02), and first HHF (OR = 0.73, 95% CI: 0.51 to 1.05), and an improved left ventricular ejection fraction (LVEF) (MD = 4.54, 95% CI: −0.13 to 9.21). Meta‐regression showed a significant inverse moderating effect of baseline LVEF on the first HHF or CV death. In patients with HF and iron deficiency, IV iron therapy reduced the incidence of composite of first HHF or CV mortality. There was a trend of lower overall CV and 1‐year all‐cause mortality, first HHF, and improved LVEF with IV iron therapy.</p><h2>Other Information</h2><p dir="ltr">Published in: ESC Heart Failure<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/ehf2.14905" target="_blank">https://dx.doi.org/10.1002/ehf2.14905</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_351d75e8bc0138e4568d82e98d774af0 |
| identifier_str_mv | 10.1002/ehf2.14905 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29899172 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Intravenous iron therapy for heart failure and iron deficiency: An updated meta‐analysis of randomized clinical trialsMushood Ahmed (19231379)Aimen Shafiq (21767660)Hira Javaid (16729233)Priyansha Singh (8265666)Haania Shahbaz (22045970)Muhammad Talha Maniya (22045973)Hritvik Jain (19757091)Najwa Shakir (22045976)Huzaifa Ahmad Cheema (13129113)Adeel Ahmad (3953720)Wajeeh Ur Rehman (18702910)Gabriel Yeap (22045979)Abdulqadir J. Nashwan (11659453)Abdul Mannan Khan Minhas (11640598)Raheel Ahmed (450330)Marat Fudim (12051803)Gregg C. Fonarow (8135523)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesFerric carboxymaltoseHeart failureIron deficiencyIntravenous iron<p dir="ltr">Heart failure (HF) patients frequently exhibit iron deficiency, which is associated with a poor prognosis. Although various trials have been conducted, it is uncertain if intravenous (IV) iron replenishment improves clinical outcomes in HF patients with iron deficiency. A comprehensive literature search was conducted using PubMed/MEDLINE, Embase, and the Cochrane Library from inception till 15 September 2023 to retrieve randomized controlled trials (RCTs) that compared IV iron therapy with placebo or standard of care in patients with HF and iron deficiency. Clinical outcomes were assessed by generating forest plots using the random‐effects model and pooling odds ratios (ORs) or weighted mean differences (WMDs). Fourteen RCTs with 6651 patients were included. IV iron therapy showed a significantly reduced incidence of the composite of first heart failure hospitalization (HHF) or cardiovascular (CV) mortality as compared with the control group (OR = 0.73, 95% CI: 0.58 to 0.92). The IV iron therapy resulted in a trend towards lower CV mortality (OR = 0.88, 95% CI: 0.76 to 1.01), 1‐year all‐cause mortality (OR = 0.85, 95% CI: 0.71 to 1.02), and first HHF (OR = 0.73, 95% CI: 0.51 to 1.05), and an improved left ventricular ejection fraction (LVEF) (MD = 4.54, 95% CI: −0.13 to 9.21). Meta‐regression showed a significant inverse moderating effect of baseline LVEF on the first HHF or CV death. In patients with HF and iron deficiency, IV iron therapy reduced the incidence of composite of first HHF or CV mortality. There was a trend of lower overall CV and 1‐year all‐cause mortality, first HHF, and improved LVEF with IV iron therapy.</p><h2>Other Information</h2><p dir="ltr">Published in: ESC Heart Failure<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/ehf2.14905" target="_blank">https://dx.doi.org/10.1002/ehf2.14905</a></p>2024-07-04T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/ehf2.14905https://figshare.com/articles/journal_contribution/Intravenous_iron_therapy_for_heart_failure_and_iron_deficiency_An_updated_meta_analysis_of_randomized_clinical_trials/29899172CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/298991722024-07-04T03:00:00Z |
| spellingShingle | Intravenous iron therapy for heart failure and iron deficiency: An updated meta‐analysis of randomized clinical trials Mushood Ahmed (19231379) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Ferric carboxymaltose Heart failure Iron deficiency Intravenous iron |
| status_str | publishedVersion |
| title | Intravenous iron therapy for heart failure and iron deficiency: An updated meta‐analysis of randomized clinical trials |
| title_full | Intravenous iron therapy for heart failure and iron deficiency: An updated meta‐analysis of randomized clinical trials |
| title_fullStr | Intravenous iron therapy for heart failure and iron deficiency: An updated meta‐analysis of randomized clinical trials |
| title_full_unstemmed | Intravenous iron therapy for heart failure and iron deficiency: An updated meta‐analysis of randomized clinical trials |
| title_short | Intravenous iron therapy for heart failure and iron deficiency: An updated meta‐analysis of randomized clinical trials |
| title_sort | Intravenous iron therapy for heart failure and iron deficiency: An updated meta‐analysis of randomized clinical trials |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Ferric carboxymaltose Heart failure Iron deficiency Intravenous iron |